Politico spoke with Akerman Healthcare Practice Chair Robert Slavkin recently about the Biden Administration's price negotiations with drug makers. The White House announced last month it had negotiated lower prices on 10 widely-prescribed drugs, claiming $6 billion in Medicare savings beginning in 2026.

Some question how Pharmacy Benefit Managers will respond, noting PBMs may steer patients away from the lower-priced drugs. Slavkin is less skeptical, pointing out how the industry is already responding to calls from Congress for increased transparency. 

“You’re seeing an effort industry-wide to play ball,” he told Politico.

Article available to PoliticoPro subscribers.